Call for pull incentives to get started
With new backing from large pharma, rising investors interest, and new incubators on stage, the AMR community is now urging policy makers worldwide to bring pull incentives into reality.
ADVERTISEMENT
About Thomas Gabrielczyk
This author has not written his bio yet.
But we are proud to say that Thomas Gabrielczyk contributed 2080 entries already.
Entries by Thomas Gabrielczyk
Cardior bags €64m in Series B Financing
Cardior Pharmaceuticals GmbH is funding a Phase II trial with lead candidate CDR132L against mi-R132-induced heart failure.
ERS Genomics and Cellular Engineering Technologies collaborating
ERS Genomics and Cellular Engineering Technologies have entered into a CRISPR-Cas9 license agreement.
Visus Therapeutics cashes in €20m from LSP
Visus Therapeutics has baged a €20m stock financing to advance development of Brimochol for presbyopia
British drug developer Mission Therapeutics plc earns $20m milestone
British drug developer Mission Therapeutics plc has bagged a $20m milestone payment from Abbvie within the companies’ neurodegenerative disease collaboration.
Bayer takes over Vividion
The big pharma company is shelling out US$1.5bn in the acquisition of US screening specialist Vividion Therapeutics.
Spectricity raises €14m in Series B round
Belgian semiconductor specialist Spectricity BV has baged €14m to speed up the development of mobile hyperspectral sensors for medical applications.
BioFlo® 720: Experience Seamless Scalability of Your Bioprocess
Efficient and reliable scale-up is one of the major hurdles in modern biotechnology. Engineering parameters such as impeller tip speed, oxygen transfer rate, impeller power number (Np) and the impeller power consumption per volume (P/V) are just a few of the parameters that need to be considered to ensure a successful tech transfer from bench to pilot and production scale. The BioFlo® 720 bioreactor control system was designed to save time and to mitigate risks.
Abcam to acquire BioVision for $340m
Life sciences tool provider Abcam plc has entered into a definitive agreement to acquire BioVision, Inc. for $340m.